GlassScriptPhysician profile
Tracy M Katz
NPI 1578792776
$87,553.38
in general payments reported to CMS, 2019-2025
29 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $1,089 · 2021: $570 · 2022: $4,965 · 2023: $48K · 2024: $1,162 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $2,613 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $47,194.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,958.00 |
| Food and Beverage | $2,613.46 |
| Education | $116.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be LTD | $80,152.00 | 2022-2025 | M22 |
| Merz North America, INC. | $1,748.33 | 2019-2024 | |
| Abbvie INC. | $1,132.19 | 2019-2025 | |
| Galderma Laboratories, L.P. | $813.19 | 2019-2025 | Nemluvio, Dysport, Oracea |
| Almirall LLC | $452.95 | 2019-2025 | Seysara, Klisyri |
| Janssen Biotech, INC. | $452.87 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Allergan, INC. | $400.70 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $301.67 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $269.57 | 2019-2023 | |
| Pfizer INC. | $206.41 | 2019-2023 | |
| Amgen INC. | $187.98 | 2020-2024 | Otezla |
| Leo Pharma INC. | $159.12 | 2019-2025 | Anzupgo |
| Sun Pharmaceutical Industries INC. | $147.88 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $142.94 | 2019-2025 | Bimzelx |
| Encore Dermatology INC. | $129.84 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $128.93 | 2019-2020 | |
| Incyte Corporation | $125.08 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $110.00 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $99.26 | 2023-2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $83.47 | 2023 | Sotyktu |
| Dermira, INC. | $75.71 | 2019-2020 | |
| Genzyme Corporation | $59.48 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.03 | 2019-2024 | Cabtreo |
| Lilly USA, LLC | $43.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $21.33 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.70 | 2019 | |
| Vyne Pharmaceuticals INC. | $19.60 | 2021 | |
| Botanix Sb INC | $17.09 | 2025 | Sofdra |
| Organon LLC | $4.69 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.